Physician profile
Christopher A Aoki
NPI 1164460499
$6,767.02
in general payments reported to CMS, 2019-2025
26 companies · $1,839 in 2025
The $1,839 reported for 2025 was more than what 77% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $541 · 2020: $505 · 2021: $684 · 2022: $455 · 2023: $1,222 · 2024: $1,522 · 2025: $1,839.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,483 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,483.42 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,917.14 | 2019-2025 | Rinvoq, Skyrizi |
| Gilead Sciences, INC. | $1,758.20 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $467.30 | 2019-2025 | Entyvio, Gattex |
| Janssen Biotech, INC. | $414.41 | 2024-2025 | Tremfya |
| Pfizer INC. | $304.20 | 2019-2025 | |
| Madrigal Pharmaceuticals | $252.18 | 2024-2025 | Rezdiffra, Resmetirom |
| Celgene Corporation | $198.94 | 2022-2024 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $188.42 | 2023-2025 | Dupixent |
| Boston Scientific Corporation | $176.28 | 2023 | Resolution Clip |
| Intercept Pharmaceuticals, INC. | $147.89 | 2020-2025 | Ocaliva |
| Genzyme Corporation | $118.08 | 2022-2023 | |
| Steris Corporation | $104.12 | 2022 | |
| Olympus America INC. | $101.33 | 2019 | |
| Mirum Pharmaceuticals, INC. | $99.60 | 2024-2025 | Livmarli |
| Ipsen Biopharmaceuticals, INC | $88.28 | 2024-2025 | Iqirvo |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $86.66 | 2023-2024 | Terlivaz |
| Astrazeneca Pharmaceuticals LP | $84.99 | 2023-2025 | Imfinzi |
| Celltrion USA INC. | $60.28 | 2025 | Vegzelma |
| Genentech, INC. | $49.54 | 2023-2025 | Tecentriq, Avastin |
| Lilly USA, LLC | $33.41 | 2024 | Omvoh |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.78 | 2023-2024 | Xifaxan, Trulance |
| Janssen Scientific Affairs, LLC | $25.81 | 2022 | |
| Novo Nordisk INC | $19.57 | 2025 | Wegovy |
| E.R. Squibb & Sons, L.L.C. | $15.29 | 2019 | |
| Ironwood Pharmaceuticals, INC | $13.15 | 2020 | |
| Dova Pharmaceuticals | $11.17 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Aoki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.